Menu

Media

Latest press releases, media assets and global media contacts

Press releasesAnnual Report 2025
Two scientists in a lab
Close video

Scroll to explore

Latest press releases

For media and investors

08 April 2026

Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)

30 March 2026

Exdensur (depemokimab) approved in China for the treatment of severe asthma

30 March 2026

Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B

27 March 2026

Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B

23 March 2026

GSK’s B7-H3-targeted antibody-drug conjugate, risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan

19 March 2026

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

13 March 2026

GSK’s RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18–49 years at increased risk

10 March 2026

GSK tops Antimicrobial Resistance (AMR) Benchmark Report

09 March 2026

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

03 March 2026

GSK completes acquisition of RAPT Therapeutics

26 February 2026

Bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B

26 February 2026

Linerixibat accepted for priority review in China for cholestatic pruritus in patients with primary biliary cholangitis

25 February 2026

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

25 February 2026

ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen

25 February 2026

GSK enters agreement to acquire 35Pharma Inc.

18 February 2026

ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM

17 February 2026

GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows

17 February 2026

Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

10 February 2026

GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older

06 February 2026

Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)

04 February 2026

GSK delivers strong 2025 performance and re-affirms long-term outlooks

26 January 2026

GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older

23 January 2026

Trelegy Ellipta approved in China for use in adults with uncontrolled asthma

20 January 2026

GSK enters agreement to acquire RAPT Therapeutics

20 January 2026

GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding

07 January 2026

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission

07 January 2026

GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B

06 January 2026

Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps

05 January 2026

Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)

19 December 2025

GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans

16 December 2025

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

15 December 2025

Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

12 December 2025

Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)

12 December 2025

Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

12 December 2025

GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older

11 December 2025

Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC)

10 December 2025

GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA

01 December 2025

GSK data at ASH show potential to redefine outcomes for people living with blood cancers

20 November 2025

TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.

19 November 2025

GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology

18 November 2025

GSK and Fleming Initiative scientists unite to target AMR with advanced AI

07 November 2025

GSK presents data from its advancing liver pipeline at AASLD 2025

29 October 2025

GSK delivers strong Q3 performance and upgrades 2025 guidance

28 October 2025

GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases

28 October 2025

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU

27 October 2025

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

23 October 2025

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

22 October 2025

GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler

21 October 2025

GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion

21 October 2025

Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)

Behind the Science

Read our latest articles

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

Behind the Science magazine
Office Image Person Talking With Co Worker

Media Contacts

Are you a professional journalist with an enquiry for our media team?

Get in touch

Media library

Explore our images and videos for use in the media. 

Scientists Collaborating And Conducting Vaccine Research

Image

Scientists collaborating and conducting vaccine research

Scientist working in Jurong lab

Image

Vaccines manufacturing, Jurong

Man sitting at desk with laptop and computer screen

Image

AI Hub, Kings Cross, London

Manufacturing Employee At Work, Singapore

Image

Manufacturing employee at work, singapore

Stevenage R&D site, UK

Image

Stevenage R&D site, UK

Luke Miels

Image

Luke Miels

Our media library

In the spotlight

Luke Miels

2026 First quarter results announcement

Quarterly results
29 April 2026

​We will announce our first quarter results at 07:00 BST, 02:00 EST on Wednesday 29 April. ​

Following the announcement there will be a webcast hosted by Luke Miels, CEO, and other members of the Executive Committee at 12:00 BST, 07:00 EDT.

Science Image Multiple Myeloma RGB

2025 Annual Report and Responsible Business Performance Report published

Annual Report 2025
05 March 2025
Male scientist and female dressed smartly smiling in a studio

GSK at a glance

Quick facts and figures with a downloadable PDF

GSK at a glance

You might also like

Our leading scientists

Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.

GSK at a glance

We prioritise innovation in specialty medicines and vaccines to prevent and treat disease.

Global health

We are changing the trajectory of high burden diseases in lower income countries, with a focus on infectious diseases.

Continue to Careers